Evidence map›Paper›PMID 31384397›Full record

ArticleOncotarget2019

Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma.

Omkara Lakshmi Veeranki, Zhimin Tong, Rashmi Dokey, Alicia Mejia, Jianhu Zhang, Yawei Qiao, Pankaj Kumar Singh, Riham Katkhuda, Barbara Mino, Ramesh Tailor and 11 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Esophageal adenocarcinoma models: a closer look.Frontiers in molecular biosciences · 2024
    Review
  6. Article
  7. Review
  8. Review
  9. P-TEFb as A Promising Therapeutic Target.Molecules (Basel, Switzerland) · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 1 institution in 1 country.

Omkara Lakshmi VeerankiDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Zhimin TongDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Rashmi DokeyDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Alicia MejiaDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jianhu ZhangExperimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Yawei QiaoExperimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Pankaj Kumar SinghExperimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Riham KatkhudaTranslational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Barbara MinoTranslational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ramesh TailorRadiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jaime Rodriguez CanalesTranslational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Roland BassettBiostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jaffer AjaniGastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ji Yuan WuGastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Scott KopetzGastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Mariela BlumGastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Wayne HofstetterThoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Michael TetzlaffDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Sunil KrishnanRadiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Steven H LinRadiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Dipen MaruDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Center for Clinical and Translational Sciences (CCTS)KL2TR000370 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$4.3M
Functional Proteomics by Reverse Phase Protein Array in CancerR50CA221675 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LU, YILING · 2017 to 2021
$726k
NCATS NIH HHS KL2 TR000370NCI NIH HHS P30 CA016672NCI NIH HHS R50 CA221675
6 · The paper itself

Abstract

Cyclin-dependent kinase 9 (CDK9) transcriptionally regulates several proteins and cellular pathways central to radiation induced tissue injury. We investigated a role of BAY1143572, a new highly specific CDK9 inhibitor, as a sensitizer to radiation in esophageal adenocarcinoma.

Indexed as

AxlCDK 9 Inhibitoresophageal adenocarcinomaradiation

Identifiers

PMID31384397
PMCPMC6659793
OpenAlexW2972566023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.